Galecto, PharmAkea Merger Creates Single Company with Strong Fibrotic Disease, Cancer Pipelines

Galecto Biotech and PharmAkea, two clinical-stage pharmaceutical companies with robust pipelines in fibrotic diseases and cancer, have merged into a single company.

Following the merger, the combined company will maintain the Galecto name, as well as its current senior management team, which includes Hans Schambye as CEO. Galecto, Inc. will be incorporated in the United States, but will keep its operational headquarters in Copenhagen, Denmark.

Read more